Canaccord Genuity Downgrades Orexigen Therapeutics (OREX) to Hold; Worst Case Scenario Occurred
Tweet Send to a Friend
Canaccord Genuity downgraded Orexigen Therapeutics (NASDAQ: OREX) from Buy to Hold.
Canaccord analyst says, "The worst case has occurred and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "The worst case has occurred and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
